Abstract
Summary
This report is an essential source for in-depth information and data relating
to the Brazil Drug Delivery Devices devices market. It also offers detailed
and comprehensive coverage of market revenue, volume, distribution and company
share information; and latest news, financial deals and pipeline products
information of each of the key sub-segments of the Drug Delivery Devices in
Brazil
Scope
・ The report provides drug delivery devices information broken down into
detailed categories and segments in Brazil.
・ Total revenues, products
sold, end users, and average pricing.
・ Market shares of all the key
competitors.
・ Key pipeline products that are set to shape the market,
broken down by sector.
・ Information on the top medical equipment
companies in the sector in the country covering business description,
strategic analysis, and financial information.
・ Healthcare structure,
regulatory environment, approval process, pricing trends and
reimbursement.
・ Product and brand updates, strategy changes, R&D
projects, corporate expansions and contractions and regulatory changes.
Key mergers and acquisitions, partnerships, private equity investments and
IPOs.
・ Customer, hospitals and physicians data.
Reasons to
buy
・ Gain a strong understanding of the drug delivery devices market in
Brazil.
・ Evaluate and compare the attractiveness of the market in the
country.
・ Identify growth segments and opportunities in each industry
sector within the country.
・ Evaluate the pipeline of key products that
will change the sector, and identify threats and opportunities before the
products are launched in the country.
・ Analyze the competitiveness of the
market in the country and identify hotspots.
・ Develop strategies based
on the latest product, brand, expansion and research and development news in
the country.
・ Do deals with an understanding of how competitors are
financed, and the mergers and partnerships that have shaped the market in the
country.
・ Identify and analyze the strengths and weaknesses of the
industry incumbents in the country.
Table of Contents
1 Table Of Contents
1 Table Of Contents 2
1.1 List of Tables 12
1.2 List of Figures 14
2 Introduction 16
2.1 What Is This Report
About? 16
2.2 Definitions 16
2.2.1 Drug delivery devices 16
2.2.1.1 Needle-free Injections 16
2.2.1.2 Inhalation Systems 16
2.2.1.3 Infusion Systems 17
3 Healthcare Sector Review 18
3.1
Healthcare Expenditure 18
3.2 Healthcare Infrastructure 19
3.3
Healthcare Policy 19
4 Drug Delivery De in Brazil 20
4.1 Drug Delivery
Devices Overall Revenues (2000-2012) 20
4.2 Drug Delivery Devices Overall
Volume (2000-2012) 26
4.3 Drug Delivery Devices Company Shares (2005-2006)
29
5 Inhalation Systems in Brazil 30
5.1 Inhalation Systems Overall
Revenues (2000-2012) 30
5.1.1 Metered Dose Inhaler Devices Overall
Revenues (2000-2012) 34
5.1.2 Dry Powder Inhaler Devices Overall Revenues
(2000-2012) 36
5.2 Inhalation Systems Overall Volume (2000-2012) 38
5.2.1 Metered Dose Inhaler Devices Overall Volume (2000-2012) 40
5.2.2 Dry
Powder Inhaler Devices Overall Volume (2000-2012) 42
5.3 Inhalation
Systems Average Price (2000-2012) 44
5.3.1 Metered Dose Inhaler Devices
Average Price (2000-2012) 44
5.3.2 Dry Powder Inhaler Devices Average
Price (2000-2012) 46
5.4 Inhalation Systems Distribution Share (2005-2006)
48
5.5 Inhalation Systems Company Share (2005-2006) 49
6 Infusion
Systems in Brazil 50
6.1 Infusion Systems Overall Revenues (2000-2012)
50
6.1.1 Infusion Disposable Sets Overall Revenue (2000-2012) 54
6.1.2
Infusion Pumps Overall Revenue (2000-2012) 56
6.1.3 Syringe Pumps Overall
Revenues (2000-2012) 58
6.2 Infusion Systems Overall Volume (2000-2012)
60
6.2.1 Infusion Disposables Sets Overall Volume (2000-2012) 61
6.2.2
Infusion Pumps Overall Volume (2000-2012) 63
6.2.3 Syringe Pumps Overall
Volume (2000-2012) 65
6.3 Infusion Systems Average Price (2000-2012)
67
6.3.1 Infusion Pumps Average Price (2000-2012) 67
6.3.2 Syringe
Pumps Average Price (2000-2012) 69
6.3.3 Infusion Disposable Sets Average
Price (2000-2012) 71
6.4 Infusion Systems Distribution Share (2005-2006)
73
6.5 Infusion Systems Company Share (2005-2006) 74
7 AstraZeneca PLC
Company Profile 75
7.1 Company Overview 75
7.2 Business Overview
75
7.2.1 Products 77
7.2.2 History 78
7.3 Locations And
Subsidiaries 79
7.4 Financial Deals Landscape 81
7.4.1 AstraZeneca
Completes $6,900 Million Private Placement 81
7.4.2 AstraZeneca Acquires
MedImmune 82
7.4.3 AstraZeneca Acquires Biologics Manufacturing Facility
From DSM Biologics 84
7.4.4 AstraZeneca Acquires Arrow Therapeutics 85
7.4.5 AstraZeneca Signs An Agreement With Palatin Technologies 87
7.4.6
AstraZeneca Signs An Agreement With Bristol-Myers Squibb 88
7.4.7
AstraZeneca Signs An Agreement With Cubist Pharmaceuticals 90
7.4.8
AstraZeneca Signs An Agreement With Par Pharmaceutical 91
7.4.9 Schering
Signs An Agreement With AstraZeneca 92
7.4.10 AstraZeneca Signs An
Agreement With Pozen 94
7.4.11 AstraZeneca Signs An Agreement With Abbott
95
7.4.12 AstraZeneca To Sell Its U.S Anaesthetic and Analgesic Product
Portfolio To Abraxis BioScience 97
7.4.13 AstraZeneca Acquires KuDOS
Pharmaceuticals 98
7.4.14 AstraZeneca Acquires A Stake In Protherics
100
7.4.15 AstraZeneca Signs An Agreement With Targacept 102
7.4.16
AstraZeneca Signs An Agreement With AtheroGenics 103
7.4.17 AstraZeneca UK
Signs An Agreement With Protherics 105
7.4.18 AstraZeneca Signs An
Agreement With Bayer Schering Pharma Aktiengesellschaft 106
7.4.19
AstraZeneca Signs An Agreement With Astex Therapeutics 108
7.4.20
AstraZeneca Signs An Agreement With Avanir Pharmaceuticals 109
7.4.21
AstraZeneca And Royal Cosun Sells Joint Venture Advanta To Syngenta 111
7.4.22 AstraZeneca Completes Private Placement Of $750 million 113
7.4.23
AstraZeneca Prices EUR750 Million Private Placement 114
7.4.24 AstraZeneca
Prices Sterling Bond GBP350 Million And Euro750 Million Eurobond Private
Placement 115
7.5 Recent Developments 117
7.5.1 Feb 22, 2008:
AstraZeneca To Appeal Judgment In Alabama Medical Pricing Case 117
7.5.2
Feb 18, 2008: AstraZeneca Appoints Non-Executive Director 117
7.5.3 Dec
12, 2007: AstraZeneca Files Patent Infringement Actions in Response to Crestor
ANDAs 117
7.5.4 Sep 28, 2007: AstraZeneca Appoints New CFO 118
7.5.5
Jul 25, 2007: AstraZeneca Appoints New Board Member 119
7.5.6 Jun 06,
2007: AstraZeneca CFO Resigns 119
7.5.7 Feb 22, 2007: AstraZeneca To
Invest $120 Miilion For R&D In Macclesfield Site 119
7.5.8 Jan 30, 2007:
Philips And Leading Healthcare Companies Join For Major Research And
Development 120
7.5.9 Jan 22, 2007: AstraZeneca Makes $100 Million
Research Investment In Boston 121
8 3M Company Profile 122
8.1 Company
Overview 122
8.2 Business Overview 122
8.2.1 Consumer and Office
122
8.2.1.1 Overview 122
8.2.1.2 Capital Expenditure 122
8.2.1.3
Market View 122
8.2.1.4 Key Strategies 122
8.2.2 Display and Graphics
122
8.2.2.1 Overview 123
8.2.2.2 Financials 123
8.2.2.3 Capital
Expenditure 123
8.2.2.4 Market View 123
8.2.2.5 Key Strategies 123
8.2.3 Electro and Communications 123
8.2.3.1 Overview 123
8.2.3.2
Financials 123
8.2.3.3 Capital Expenditure 123
8.2.3.4 Market View
123
8.2.3.5 Key Strategies 124
8.2.4 Health Care 124
8.2.4.1
Overview 124
8.2.4.2 Financials 124
8.2.4.3 Capital Expenditure
124
8.2.4.4 Market View 124
8.2.4.5 Key Strategies 125
8.2.5
Industrial and Transportation 125
8.2.5.1 Overview 125
8.2.5.2
Financials 125
8.2.5.3 Capital Expenditure 125
8.2.5.4 Market View
125
8.2.5.5 Key Strategies 125
8.2.6 Safety, Security and Protection
Services 125
8.2.6.1 Overview 125
8.2.6.2 Financials 126
8.2.6.3
Capital Expenditure 126
8.2.6.4 Market View 126
8.2.6.5 Key Strategies
126
8.2.7 Products 126
8.3 Value Chain Analysis 128
8.3.1
Manufacturing 128
8.3.1.1 In House Manufacturing 128
8.3.2 Product
Development 128
8.3.2.1 Regulatory Approvals 129
8.3.2.2 Clinical
Trials 129
8.3.2.3 Research and Development 129
8.3.3 Sales and
Marketing 129
8.3.3.1 Partnerships and Alliances 129
8.3.3.2 Licensing
Agreements 129
8.3.3.3 E-distribution 130
8.4 SWOT Analysis 131
8.4.1 3M Company Strengths 131
8.4.1.1 Strong performance of Industrial
and Transportation segment 131
8.4.1.2 Focused research and development
131
8.4.1.3 Decentralized operations 132
3M Company Weaknesses 132
8.4.1.4 Increased operating costs in the U.S. 132
8.4.1.5 Personal care
segment' s poor performance 132
3M Company Opportunities 132
8.4.1.6
Expanding global presence 132
8.4.1.7 The liquid crystal display 132
8.4.1.8 Enhancing brand portfolio 133
3M Company Threats 133
8.4.1.9
Foreign currency fluctuations 133
8.4.1.10 Increasing cost of raw
materials 133
8.4.1.11 Trend for private labels 133
8.5 Revenue
Analysis 134
8.5.1 Revenue by Segment 134
8.5.2 Revenue by Geography
135
8.6 Financial and Operational Review 136
8.6.1 Financial
Statements 136
8.6.2 Financial Ratios 137
8.7 Locations And
Subsidiaries 138
8.8 Financial Deals Landscape 139
8.8.1 3M Canada
Acquires Les Entreprises Solumed 139
8.8.2 3M Acquires Bondo 140
8.8.3
3M Acquires Lingualcare 142
8.8.4 3M Acquires Abzil Industria E Comercio
144
8.8.5 3M Acquires Neo Plast 146
8.8.6 3M Acquires Assets Of DMS
Chile 148
8.8.7 3M Acquires Business Of Innovative Paper Technologies
150
8.8.8 3M Acquires Powell 152
8.8.9 Gen-Probe Signs An Agreement
With 3M Company 154
8.8.10 3M Acquires Acolyte Biomedica 156
8.8.11 3M
Acquires Sealed Air Corp.' S Interest In Polymask Corp. 158
8.8.12 3M Sells
Its Pharmaceutical Business To Meda AB 160
8.8.13 3M Acquires SoftMed
Systems 162
8.8.14 3M Sells its Pharmaceuticals Business to Graceway
164
8.8.15 Gen-Probe Signs An Agreement With 3M 166
8.8.16 3M Sells
its Pharmaceutical Operations in the Asia Pacific Region to Ironbridge Capital
and Archer Capital 168
8.8.17 3M Acquires Biotrace International 170
8.8.18 Ekahau Secures $16 Million In Additional Funding 171
8.8.19 3M
Acquires Brontes Technologies 174
8.8.20 3M acquires Nylonge Corp 176
8.8.21 3M Signs An Agreement With ClozeX Medical 178
8.8.22 3M Acquires
OMNII Oral Pharmaceuticals 180
8.8.23 3M Sells Pharmaceutical Operations
In The United States To Graceway 182
8.8.24 3M Sells Pharmaceutical
Business In Europe To Meda AB 184
8.8.25 3M Sells Pharmaceutical
Operations In The Asia Pacific To Ironbridge and Archer Capital 187
8.8.26 3M Acquires Accuspray Application Technologies Inc. 190
8.8.27 3M
to acquire Rochford Thompson Equipment 191
8.8.28 3M To Acquire Aearo
Technologies From Permira 193
8.8.29 Permira To Sell Aearo Technologies To
3M 195
8.9 Recent Developments 198
8.9.1 Mar 31, 2008: HighJump
Software Introduces Survey Management Solution for Direct Store Delivery
Businesses 198
8.9.2 Mar 24, 2008: Brazil' s Companhia de Transmissao de
Energia Eletrica Paulista Chooses 3M ACCR for Upgrade of Line Over Parana
River in Sao Paulo State 198
8.9.3 Mar 19, 2008: 3M to Headquarter Optical
Systems Business in Asia 200
8.9.4 Mar 19, 2008: 3M To Headquarter Optical
Systems Business In North Asia 200
8.9.5 Feb 11, 2008: 3M Increases
Dividend for the 50th Straight Year 200
8.9.6 Nov 12, 2007: 3M Declares
Quarterly Dividend 200
8.9.7 Oct 24, 2007: 3M And Sanyo Settle Suit On
Lithium Ion Battery 200
8.9.8 Aug 13, 2007: 3M Declares Quarterly Dividend
201
8.9.9 May 08, 2007: 3M Declares Quarterly Dividend 201
8.9.10 Apr
30, 2007: Gen-Probe And 3M Collaborate To Develop Rapid Molecular Tests
201
9 Baxter International Company Profile 202
9.1 Company Overview
202
9.2 Business Overview 202
9.2.1 BioScience 202
9.2.1.1
Overview 202
9.2.1.2 Financials 202
9.2.1.3 Capital Expenditure
202
9.2.2 Medication Delivery 202
9.2.2.1 Overview 202
9.2.2.2
Financials 202
9.2.2.3 Capital Expenditure 203
9.2.3 Renal 203
9.2.3.1 Overview 203
9.2.3.2 Financials 203
9.2.3.3 Capital
Expenditure 203
9.2.4 Products 204
9.2.5 History 205
9.3 Value
Chain Analysis 208
9.3.1 Manufacturing 208
9.3.1.1 In House
Manufacturing 208
9.3.2 Product Development 208
9.3.2.1 Regulatory
Approvals 208
9.3.2.2 Clinical Trials 209
9.3.2.3 Research and
Development 209
9.3.3 Sales and Marketing 209
9.3.3.1 Partnerships and
Alliances 209
9.4 SWOT Analysis 211
9.4.1 Baxter International Inc.
Strengths 211
9.4.1.1 Diversified geographic presence 211
9.4.1.2
Sturdy research and development activities 211
9.4.1.3 Strong financial
performance 211
9.4.2 Baxter International Inc. Weaknesses 212
9.4.2.1
High levels of inventory 212
9.4.2.2 Decline in revenues of medication
delivery 212
9.4.2.3 Reduced capital expenditure 212
9.4.3 Baxter
International Inc. Opportunities 212
9.4.3.1 Co-developing alliances
212
9.4.3.2 Increasing End Stage Renal Disease patients 212
9.4.3.3
FDA approval 213
9.4.4 Baxter International Inc. Threats 213
9.4.4.1
Legal proceedings 213
9.4.4.2 Patent litigation 213
9.4.4.3 Stringent
regulations 213
9.5 Revenue Analysis 214
9.5.1 Revenue by Segment
214
9.5.2 Revenue by Geography 215
9.6 Financial and Operational
Review 216
9.6.1 Financial Statements 216
9.6.2 Financial Ratios
217
9.7 Locations And Subsidiaries 218
9.8 Financial Deals Landscape
220
9.8.1 Baiyunshan And Baxter Form A Joint Venture In China 220
9.8.2 Baxter Signs Licensing Agreement With Intercytex And Spinal Restoration
221
9.8.3 Baxter Sells Transfusion Therapies Business to Texas Pacific and
Maverick Capital 223
9.8.4 B. Braun Acquires Renal Therapy Business Of
Baxter 225
9.8.5 Innovata signs a license agreement with Baxter
International 226
9.8.6 Kuros Biosurgery Signs An Agreement With Baxter
International 228
9.8.7 Gambro Signs An Agreement With Baxter 229
9.8.8 Baxter Healthcare And Gambro Enter Into An Agreement 231
9.8.9
Baxter and Cerus Enter Into Agreement With BioOne for Commercialization Of
INTERCEPT Blood System 232
9.8.10 Baxter International And Kaketsuken
Enter Into Agreement 234
9.8.11 Baxter To Acquire 40% Stake In Shanghai
Baxter From Worldbest Treeful 235
9.9 Recent Developments 237
9.9.1
Jan 24, 2008: Baxter Achieves Record Sales and Earnings for Full-Year 2007
237
9.9.2 Dec 18, 2007: Baxter Elects CFO 239
9.9.3 Nov 13, 2007:
Baxter Declares Quarterly Dividend 239
9.9.4 Aug 01, 2007: Baxter Elects
New Board Director 239
9.9.5 Jul 31, 2007: Baxter Announces Quarterly
Dividend 240
9.9.6 Mar 13, 2007: Baxter Declares Additional Share
Repurchase Authorization 240
9.9.7 Feb 13, 2007: Baxter Announces
Quarterly Dividend 240
9.9.8 Nov 28, 2006: Baxter Announces Annual
Dividend 241
9.9.9 Sep 14, 2006: Baxter Appoints President, Baxter Latin
America 241
9.10 Baxter International Inc. Pipeline Products 243
9.10.1 Next-Generation Home Hemodialysis Machine 243
9.10.1.1 Product
Overview 243
9.10.1.2 Product Description 243
9.10.1.3 Product Status
243
9.10.1.4 Product Milestone 243
10 GlaxoSmithKline plc Company
Profile 245
10.1 Company Overview 245
10.2 Business Overview 245
10.2.1 Products 246
10.2.2 History 246
10.3 Locations And Subsidiaries
249
10.4 Financial Deals Landscape 251
10.4.1 GlaxoSmithKline Acquires
CNS 251
10.4.2 Bayer HealthCare Acquires Pritor Business From
GlaxoSmithKline 252
10.4.3 CNS To Merge With GlaxoSmithKline 254
10.5
Recent Developments 256
10.5.1 Mar 19, 2008: GSK charitable support valued
at GBP282 million in 2007 256
10.5.2 Feb 07, 2008: Full-year results
announcement 2007 256
10.5.3 Dec 19, 2007: GlaxoSmithKline And Santaris
Enter Global R&D Alliance 256
10.5.4 Dec 10, 2007: GlaxoSmithKline And
OncoMed Form Strategic Alliance To Develop Cancer Stem Cell Antibody
Therapeutics 257
10.5.5 Dec 07, 2007: GlaxoSmithKline Announces Board And
Management Changes 258
11 Novartis AG Company Profile 259
11.1 Company
Overview 259
11.2 Business Overview 259
11.2.1 Major Products and
Services 260
11.3 Locations And Subsidiaries 261
11.4 Financial Deals
Landscape 263
11.4.1 Bayer Schering Pharma Acquires U.S. Biologics
Manufacturing Facility From Novartis 263
11.4.2 Novartis To Acquire
Majority Stake In Alcon From Nestle 264
11.4.3 Novartis to sell Medical
Nutrition business unit to Nestlé 266
11.4.4 Nestlé to Acquire Novartis
Medical Nutrition 268
11.4.5 Novartis to sell its division Gerber Products
Company to Nestle 269
12 Regulation System 272
12.1 Medical Device
Registration Protocol 272
12.1.1 Registration Documentation 272
12.1.2
Registration Procedure 273
12.1.3 Medical Device Registration Fee 274
13 Pricing and Reimbursement 275
14 Distribution Structure 276
15
APPENDIX 277
15.1 Global Markets Direct Research Methodology 277
15.2
Coverage 278
15.3 Secondary Research 278
15.4 Primary Research 279
15.5 Models 279
15.6 Forecasts 280
15.7 Expert Panels 280
15.8
Currency Conversion 281
15.9 Contact Us 282
15.10 Disclaimer 282
1.1 List of Tables
Table 1: Drug Delivery Devices, Brazil,
Overall Revenues ($ mn), 2000-2012 20
Table 2: Drug Delivery Devices,
Brazil, Overall Revenues ($ mn), Historic, 2000-2007 21
Table 3: Drug
Delivery Devices, Brazil, Overall Revenues ($ mn), Forecast, 2007-2012 22
Table 4: Drug Delivery Devices, Brazil, Category Revenues ($ mn), 2000-2012
23
Table 5: Drug Delivery Devices, Brazil, Category Revenues ($ mn),
Historic, 2000-2007 24
Table 6: Drug Delivery Devices, Brazil, Category
Revenues ($ mn), Forecast, 2007-2012 25
Table 7: Drug Delivery Devices,
Brazil, Category Volume (Units), 2000-2012 26
Table 8: Drug Delivery
Devices, Brazil, Category Volume (Units), Historic, 2000-2007 27
Table 9:
Drug Delivery Devices, Brazil, Category Volume (Units), Forecast, 2007-2012
28
Table 10: Drug Delivery Devices, Brazil, Company Share by Revenue ($
mn), 2005-2006 29
Table 11: Inhalation Systems, Brazil, Overall Revenues
($ mn), Historic, 2000-2007 30
Table 12: Inhalation Systems, Brazil,
Overall Revenues ($ mn), Forecast, 2007-2012 31
Table 13: Inhalation
Systems, Brazil, Revenue by Segment ($ mn), Historic, 2000-2007 32
Table
14: Inhalation Systems, Brazil, Revenue by Segment ($ mn), Forecast, 2007-2012
33
Table 15: Metered Dose Inhaler Devices, Brazil, Overall Revenues ($
mn), Historic, 2000-2007 34
Table 16: Metered Dose Inhaler Devices,
Brazil, Overall Revenues ($ mn), Forecast, 2007-2012 35
Table 17: Dry
Powder Inhaler Devices, Brazil, Overall Revenues ($ mn), Historic, 2000-2007
36
Table 18: Dry Powder Inhaler Devices, Brazil, Overall Revenues ($ mn),
Forecast, 2007-2012 37
Table 19: Inhalation Systems, Brazil, Overall
Volume (Units), Historic, 2000-2007 38
Table 20: Inhalation Systems,
Brazil, Overall Volume (Units), Forecast, 2007-2012 39
Table 21: Metered
Dose Inhaler Devices, Brazil, Overall Volume (Units), Historic, 2000-2007
40
Table 22: Metered Dose Inhaler Devices, Brazil, Overall Volume (Units),
Forecast, 2007-2012 41
Table 23: Dry Powder Inhaler Devices, Brazil,
Overall Volume (Units), Historic, 2000-2007 42
Table 24: Dry Powder
Inhaler Devices, Brazil, Overall Volume (Units), Forecast, 2007-2012 43
Table 25: Metered Dose Inhaler Devices, Brazil, Average Price ($), Historic,
2000-2007 44
Table 26: Metered Dose Inhaler Devices, Brazil, Average Price
($), Forecast, 2007-2012 45
Table 27: Dry Powder Inhaler Devices, Brazil,
Average Price ($), Historic, 2000-2007 46
Table 28: Dry Powder Inhaler
Devices, Brazil, Average Price ($), Forecast, 2007-2012 47
Table 29:
Inhalation Systems, Brazil, Distribution Share by Revenue ($ mn), 2005-2006
48
Table 30: Inhalation Systems, Brazil, Company Share by Revenue ($ mn),
2005-2006 49
Table 31: Infusion Systems, Brazil, Overall Revenues ($ mn),
Historic, 2000-2007 50
Table 32: Infusion Systems, Brazil, Overall
Revenues ($ mn), Forecast, 2007-2012 51
Table 33: Infusion Systems,
Brazil, Revenue by Segment ($ mn), Historic, 2000-2007 52
Table 34:
Infusion Systems, Brazil, Revenue by Segment ($ mn), Forecast, 2007-2012
53
Table 35: Infusion Disposable Sets, Brazil, Overall Revenues ($ mn),
Historic, 2000-2007 54
Table 36: Infusion Disposable Sets, Brazil, Overall
Revenues ($ mn), Forecast, 2007-2012 55
Table 37: Infusion Pumps, Brazil,
Overall Revenues ($ mn), Historic, 2000-2007 56
Table 38: Infusion Pumps,
Brazil, Overall Revenues ($ mn), Forecast, 2007-2012 57
Table 39: Syringe
Pumps, Brazil, Overall Revenues ($ mn), Historic, 2000-2007 58
Table 40:
Syringe Pumps, Brazil, Overall Revenues ($ mn), Forecast, 2007-2012 59
Table 41: Infusion Systems, Brazil, Overall Volume (Units), Historic,
2000-2007 60
Table 42: Infusion Systems, Brazil, Overall Volume (Units),
Forecast, 2007-2012 60
Table 43: Infusion Disposable Sets, Brazil, Overall
Volume (Units), Historic, 2000-2007 61
Table 44: Infusion Disposable Sets,
Brazil, Overall Volume (Units), Forecast, 2007-2012 62
Table 45: Infusion
Pumps, Brazil, Overall Volume (Units), Historic, 2000-2007 63
Table 46:
Infusion Pumps, Brazil, Overall Volume (Units), Forecast, 2007-2012 64
Table 47: Syringe Pumps, Brazil, Overall Volume (Units), Historic, 2000-2007
65
Table 48: Syringe Pumps, Brazil, Overall Volume (Units), Forecast,
2007-2012 66
Table 49: Infusion Pumps, Brazil, Average Price ($),
Historic, 2000-2007 67
Table 50: Infusion Pumps, Brazil, Average Price
($), Forecast, 2007-2012 68
Table 51: Syringe Pumps, Brazil, Average Price
($), Historic, 2000-2007 69
Table 52: Syringe Pumps, Brazil, Average Price
($), Forecast, 2007-2012 70
Table 53: Infusion Disposable Sets, Brazil,
Average Price ($), Historic, 2000-2007 71
Table 54: Infusion Disposable
Sets, Brazil, Average Price ($), Forecast, 2007-2012 72
Table 55: Infusion
Systems, Brazil, Distribution Share by Revenue ($ mn), 2005-2006 73
Table
56: Infusion Systems, Brazil, Company Share by Revenue ($ mn), 2005-2006
74
Table 57: AstraZeneca PLC, Subsidiaries 79
Table 58:
AstraZeneca PLC, Subsidiaries(Contd..) 80
Table 59: 3M Company, SWOT
Analysis, 2006 131
Table 60: 3M Company, Revenue by Segment, USD
Million, 2003-2007 134
Table 61: 3M Company, Revenue by Geography,
USD Million, 2003-2007 135
Table 62: 3M Company, Financial
Statements, USD Million, 2003-2007 136
Table 63: 3M Company,
Financial Ratios, USD Million, 2003-2007 137
Table 64: 3M Company,
Subsidiaries 138
Table 65: Baxter International Inc., SWOT Analysis,
2006 211
Table 66: Baxter International Inc., Revenue by Segment, USD
Million, 2003-2007 214
Table 67: Baxter International Inc., Revenue
by Geography, USD Million, 2003-2007 215
Table 68: Baxter
International Inc., Financial Statements, USD Million, 2003-2007 216
Table
69: Baxter International Inc., Financial Ratios, USD Million, 2003-2007
217
Table 70: Baxter International Inc., Other Locations 218
Table 71: Baxter International Inc., Subsidiaries 219
Table 72:
GlaxoSmithKline plc, Subsidiaries 249
Table 73: GlaxoSmithKline plc,
Subsidiaries(Contd..) 250
Table 74: Novartis Medical Nutrition, Other
Locations 261
Table 75: Novartis Medical Nutrition, Other
Locations(Contd..) 262
Table 76: Medical Device Registration Fee in
Brazil, 2002 274
Table 77: Currency Conversion from USD to Local
Currency at 2007 Constant Rate 281
1.2 List of Figures
Figure 1:
Health Expenditure by Source in Brazil, 1996 19
Figure 2: Drug Delivery
Devices, Brazil, Overall Revenues ($ mn), 2000-2012 20
Figure 3: Drug
Delivery Devices, Brazil, Overall Revenues ($ mn), Historic, 2000-2007 21
Figure 4: Drug Delivery Devices, Brazil, Overall Revenues ($ mn), Forecast,
2007-2012 22
Figure 5: Drug Delivery Devices, Brazil, Category Revenues ($
mn), 2000-2012 23
Figure 6: Drug Delivery Devices, Brazil, Category
Revenues ($ mn), Historic, 2000-2007 24
Figure 7: Drug Delivery Devices,
Brazil, Category Revenues ($ mn), Forecast, 2007-2012 25
Figure 8: Drug
Delivery Devices, Brazil, Category Volume (Units), 2000-2012 26
Figure 9:
Drug Delivery Devices, Brazil, Category Volume (Units), Historic, 2000-2007
27
Figure 10: Drug Delivery Devices, Brazil, Category Volume (Units),
Forecast, 2007-2012 28
Figure 11: Drug Delivery Devices, Brazil, Company
Share (%), 2006 29
Figure 12: Inhalation Systems, Brazil, Overall Revenues
($ mn), Historic, 2000-2007 30
Figure 13: Inhalation Systems, Brazil,
Overall Revenues ($ mn), Forecast, 2007-2012 31
Figure 14: Inhalation
Systems, Brazil, Revenue by Segment ($ mn), Historic, 2000-2007 32
Figure
15: Inhalation Systems, Brazil, Revenue by Segment ($ mn), Forecast, 2007-2012
33
Figure 16: Metered Dose Inhaler Devices, Brazil, Overall Revenues ($
mn), Historic, 2000-2007 34
Figure 17: Metered Dose Inhaler Devices,
Brazil, Overall Revenues ($ mn), Forecast, 2007-2012 35
Figure 18: Dry
Powder Inhaler Devices, Brazil, Overall Revenues ($ mn), Historic, 2000-2007
36
Figure 19: Dry Powder Inhaler Devices, Brazil, Overall Revenues ($ mn),
Forecast, 2007-2012 37
Figure 20: Inhalation Systems, Brazil, Overall
Volume (Units), Historic, 2000-2007 38
Figure 21: Inhalation Systems,
Brazil, Overall Volume (Units), Forecast, 2007-2012 39
Figure 22: Metered
Dose Inhaler Devices, Brazil, Overall Volume (Units), Historic, 2000-2007
40
Figure 23: Metered Dose Inhaler Devices, Brazil, Overall Volume
(Units), Forecast, 2007-2012 41
Figure 24: Dry Powder Inhaler Devices,
Brazil, Overall Volume (Units), Historic, 2000-2007 42
Figure 25: Dry
Powder Inhaler Devices, Brazil, Overall Volume (Units), Forecast, 2007-2012
43
Figure 26: Metered Dose Inhaler Devices, Brazil, Average Price ($),
Historic, 2000-2007 44
Figure 27: Metered Dose Inhaler Devices, Brazil,
Average Price ($), Forecast, 2007-201 2 45
Figure 28: Dry Powder Inhaler
Devices, Brazil, Average Price ($), Historic, 2000-2007 46
Figure 29: Dry
Powder Inhaler Devices, Brazil, Average Price ($), Forecast, 2007-2012 47
Figure 30: Inhalation Systems, Brazil, Distribution Share (%), 2006 48
Figure 31: Inhalation Systems, Brazil, Company Share (%), 2006 49
Figure
32: Infusion Systems, Brazil, Overall Revenues ($ mn), Historic, 2000-2007
50
Figure 33: Infusion Systems, Brazil, Overall Revenues ($ mn), Forecast,
2007-2012 51
Figure 34: Infusion Systems, Brazil, Revenue by Segment ($
mn), Historic, 2000-2007 52
Figure 35: Infusion Systems, Brazil, Revenue
by Segment ($ mn), Forecast, 2007-2012 53
Figure 36: Infusion Disposable
Sets, Brazil, Overall Revenues ($ mn), Historic, 2000-2007 54
Figure 37:
Infusion Disposable Sets, Brazil, Overall Revenues ($ mn), Forecast, 2007-2012
55
Figure 38: Infusion Pumps, Brazil, Overall Revenues ($ mn), Historic,
2000-2007 56
Figure 39: Infusion Pumps, Brazil, Overall Revenues ($ mn),
Forecast, 2007-2012 57
Figure 40: Syringe Pumps, Brazil, Overall Revenues
($ mn), Historic, 2000-2007 58
Figure 41: Syringe Pumps, Brazil, Overall
Revenues ($ mn), Forecast, 2007-2012 59
Figure 42: Infusion Disposable
Sets, Brazil, Overall Volume (Units), Historic, 2000-2007 61
Figure 43:
Infusion Disposable Sets, Brazil, Overall Volume (Units), Forecast, 2007-2012
62
Figure 44: Infusion Pumps, Brazil, Overall Volume (Units), Historic,
2000-2007 63
Figure 45: Infusion Pumps, Brazil, Overall Volume (Units),
Forecast, 2007-2012 64
Figure 46: Syringe Pumps, Brazil, Overall Volume
(Units), Historic, 2000-2007 65
Figure 47: Syringe Pumps, Brazil, Overall
Volume (Units), Forecast, 2007-2012 66
Figure 48: Infusion Pumps, Brazil,
Average Price ($), Historic, 2000-2007 67
Figure 49: Infusion Pumps,
Brazil, Average Price ($), Forecast, 2007-2012 68
Figure 50: Syringe
Pumps, Brazil, Average Price ($), Historic, 2000-2007 69
Figure 51:
Syringe Pumps, Brazil, Average Price ($), Forecast, 2007-2012 70
Figure
52: Infusion Disposable Sets, Brazil, Average Price ($), Historic, 2000-2007
71
Figure 53: Infusion Disposable Sets, Brazil, Average Price ($),
Forecast, 2007-2012 72
Figure 54: Infusion Systems, Brazil, Distribution
Share (%), 2006 73
Figure 55: Infusion Systems, Brazil, Company Share (%),
2006 74
Figure 56: 3M Company, Value Chain Analysis 128
Figure
57: Baxter International Inc., Value Chain Analysis 208
Figure 58:
Global Markets Direct Methodology 277
